Preladenant
Preladenant is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target adenosine receptor A2a, adenosine receptor A3, adenosine receptor A2b, and adenosine receptor A1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
13 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parkinson disease | D010300 | EFO_0002508 | G20 | 2 | 3 | 4 | — | — | 9 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Movement disorders | D009069 | EFO_0004280 | G25 | — | 3 | — | — | — | 3 |
| Central nervous system diseases | D002493 | — | G96.9 | — | 2 | — | — | — | 2 |
| Brain diseases | D001927 | — | G93.40 | — | 2 | — | — | — | 2 |
| Neurodegenerative diseases | D019636 | EFO_0005772 | G31.9 | — | 2 | — | — | — | 2 |
| Drug-induced akathisia | D017109 | EFO_1000903 | G25.71 | — | 2 | — | — | — | 2 |
| Nervous system diseases | D009422 | — | G00-G99 | — | 1 | — | — | — | 1 |
| Parkinsonian disorders | D020734 | — | G20.C | — | 1 | — | — | — | 1 |
| Drug-induced dyskinesia | D004409 | EFO_1000904 | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 1 | — | — | — | — | 1 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | — | — | — | — | 1 |
| Chronic renal insufficiency | D051436 | — | N18 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Preladenant |
| INN | preladenant |
| Description | Preladenant (SCH 420814) was a drug that was developed by Schering-Plough which acted as a potent and selective antagonist at the adenosine A2A receptor. It was being researched as a potential treatment for Parkinson's disease. Positive results were reported in Phase II clinical trials in humans, but it did not prove itself to be more effective than a placebo during Phase III trials, and so was discontinued in May 2013.
|
| Classification | Small molecule |
| Drug class | adenosine receptor antagonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COCCOc1ccc(N2CCN(CCn3ncc4c3nc(N)n3nc(-c5ccco5)nc43)CC2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 377727-87-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL240624 |
| ChEBI ID | — |
| PubChem CID | 10117987 |
| DrugBank | — |
| UNII ID | 950O97NUPO (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 326 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use